KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Long-Term Investments (2022 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Long-Term Investments for 4 consecutive years, with $37.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Investments fell 70.86% to $37.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.2 million, a 70.86% decrease, with the full-year FY2025 number at $37.2 million, down 70.86% from a year prior.
  • Long-Term Investments was $37.2 million for Q4 2025 at Xenon Pharmaceuticals, down from $93.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $292.8 million in Q4 2023 to a low of $37.2 million in Q4 2025.
  • A 4-year average of $137.2 million and a median of $128.9 million in 2022 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: surged 127.53% in 2023, then crashed 70.86% in 2025.
  • Xenon Pharmaceuticals' Long-Term Investments stood at $128.7 million in 2022, then soared by 127.53% to $292.8 million in 2023, then crashed by 56.46% to $127.5 million in 2024, then plummeted by 70.86% to $37.2 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Long-Term Investments are $37.2 million (Q4 2025), $93.0 million (Q3 2025), and $137.3 million (Q2 2025).